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Objective: During IVF, non-transferred embryos are usually selected for cryopreservation on the basis of morphological criteria. This investiga-
tion evaluated an application for array comparative genomic hybridization (aCGH) in assessment of surplus embryos prior to cryopreservation. 
Methods: First-time IVF patients undergoing elective single embryo transfer and having at least one extra non-transferred embryo suitable for 
cryopreservation were offered enrollment in the study. Patients were randomized into two groups: Patients in group A (n=55) had embryos 
assessed first by morphology and then by aCGH, performed on cells obtained from trophectoderm biopsy on post-fertilization day 5. Only eu-
ploid embryos were designated for cryopreservation. Patients in group B (n=48) had embryos assessed by morphology alone, with only good 
morphology embryos considered suitable for cryopreservation. 
Results: Among biopsied embryos in group A (n=425), euploidy was confirmed in 226 (53.1%). After fresh single embryo transfer, 64 (28.3%) 
surplus euploid embryos were cryopreserved for 51 patients (92.7%). In group B, 389 good morphology blastocysts were identified and a sin-
gle top quality blastocyst was selected for fresh transfer. All group B patients (48/48) had at least one blastocyst remaining for cryopreservation. 
A total of 157 (40.4%) blastocysts were frozen in this group, a significantly larger proportion than was cryopreserved in group A (p=0.017, by 
chi-squared analysis). 
Conclusion: While aCGH and subsequent frozen embryo transfer are currently used to screen embryos, this is the first investigation to quantify 
the impact of aCGH specifically on embryo cryopreservation. Incorporation of aCGH screening significantly reduced the total number of cryo-
preserved blastocysts compared to when suitability for freezing was determined by morphology only. IVF patients should be counseled that 
the benefits of aCGH screening will likely come at the cost of sharply limiting the number of surplus embryos available for cryopreservation.
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Introduction
Within the arena of assisted reproduction, several technologies have 
emerged to address the most important challenge in human fertility 
medicine: multiple gestation. Single embryo transfer, either elective 
or mandatory, has been proposed as a way to avoid this pro blem [1-
4]. Selection of an embryo for transfer or cryopreservation is typically 
done on the basis of morphology [5,6]. However, since suitable mor-
phology by itself cannot negate the potential for chromosomal error 
in the selected embryo, the transfer or cryopreservation of apparent-
ly “normal looking” embryo carries considerable risk [7]. Experience 
with IVF has shown that aneuploidy is the most common abnormali-
ty in human embryos [8-15] and this characteristic contributes sub-
stantially to poor reproductive outcomes observed in advanced fer-
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ing embryos by fluorescence in situ hybridization was a reasonable 
first answer to this challenge, but the approach was too limited be-
cause it could not screen all chromosomes at the same time. More re-
cently, single nucleotide polymorphism array and array comparative 
genomic hybridization (aCGH) have been used to achieve compre-
hensive chromosome screening to improve efficiency of embryo 
transfer [22-30]. These techniques enable subsequent frozen embryo 
transfer so that only euploid embryo(s) are used therapeutically, thus 
improving implantation and reducing risk of miscarriage. However, 
because experience using these molecular cytogenetic tests in repro-
ductive medicine remains limited, there is a critical need to validate 
embryo selection techniques before such technology enters the clin-
ical mainstream [31]. Yet while the optimal method of determining 
the chromosomal composition of the human embryo remains un-
settled, there has been little or no discussion specifically focused on 
how such technologies might affect the total number of embryos 
available for cryopreservation. Accordingly, this study compared the 
impact of aCGH on cryopreservation yield when this molecular cyto-
genetic technique was applied to young, low-risk patients undergo-




To study the impact of aCGH on embryo cryopreservation rate in 
IVF, patients at our clinics in Los Angeles and Beijing were offered en-
rollment in this prospective, single-blind investigation. Institutional 
Review Board approval was obtained before recruitment and written 
informed consent was obtained from all study participants. All pa-
tients received pre-treatment counseling about aCGH and how this 
testing technique might affect the number of embryos cryopreserv-
ed. Patients were eligible for this study if (female) age was <35 years, 
if there was a history of regular ovulation, if etiology of infertility was 
tubal factor or male factor (or both), and if no prior IVF treatment had 
been initiated. Additionally, all study subjects were required to have 
a normal 46,XX karyotype, two ovaries, a normal endometrial con-
tour, and basal serum FSH and estradiol on d2-3 at <10 IU/L and 
<60 pg/mL, respectively. IVF patients whose treatment incorporated 
donor gametes or frozen/thawed embryos were excluded. A random 
number table was used to determine patients embryo cryopreserva-
tion protocol as either 1) traditional morphology assessment plus 
aCGH (group A, n=55), or 2) conventional morphology assessment 
only (group B, n=48). Patients (but not laboratory or clinical staff) 
were blinded with regard to their randomization group, and clinical 
features of the two study groups were similar. The two cohorts were 
mutually exclusive; no study patient had embryos assigned to both 
laboratory groups.
2.	Ovarian	stimulation	and	fertilization
Baseline transvaginal ultrasound evaluation was performed before 
starting ovulation induction medications, with re-measurement of 
serum FSH, LH and estradiol on d3 of the index cycle. GnRH-agonist 
administered on d21 of the cycle immediately preceding treatment 
was used to attain pituitary downregulation, as described previously 
[32]. Periodic transvaginal ultrasound and serum estradiol measure-
ments were used to monitor follicular growth and thickness of endo-
metrial lining. When ≥3 follicles reached 19 mm mean diameter, 
periovulatory hCG was administered by subcutaneous injection of 
recombinant hCG (250 µg Ovidrel, Merck Serono, Geneva, Switzer-
land) with oocyte retrieval performed under transvaginal ultrasound 
guidance 35-36 hours later. Following removal of all cumulus cells, 
ICSI was performed with a 30° needle, and normal fertilization was 
verified 16-18 hours after injection by presence of two pronuclei and 
two polar bodies.
3.	Embryo	culture	and	trophectoderm	biopsy
Sequential media (Vitrolife, Göteborg, Sweden) was used to sup-
port all embryos to blastocyst stage. On d3 when embryos were at 
the 6-8 cell stage, a noncontact 1.48 µm diode laser (OCTAX Microsci-
ence GmbH, Bruckberg, Germany) was used to create a circular 6-9 
µm diameter opening in the zona pellucida (ZP). For embryos ran-
domized to the aCGH group, this lacuna facilitated biopsy of trophec-
toderm (TE) on d5. Between 3-5 herniated TE cells were gently aspi-
rated by pipette and, when necessary, freed from the blastocyst by 
application of several laser pulses. Harvested TE cells were washed in 
phospate buffered solution (PBS) and placed within a polymerase 
chain reaction tube with 2.5 µL 1×PBS as previously described [33]. 
The same assisted hatching protocol was used for all embryos irre-
spective of subsequent TE biopsy or conventional microscopic as-
sessment alone.
4.	aCGH	protocol
The SurePlex DNA amplification system (BlueGnome Ltd., Cambri-
dge, UK) was used on-site for whole genome amplification in accor-
dance with manufacturer’s guidelines [33,34]. Briefly, samples and 
control DNA (8 µL for each) were labeled with Cy3 and Cy5 fluoro-
phores (BlueGnome Ltd.). Labeling time was approximately 3 hours 
with DNA resuspended in dexsulphate hybridization buffer and hy-
bridized overnight under cover slides. After washing 1×10 minutes 
in saline sodium citrate (SSC)/0.05% Tween-20 at room temperature, 
an additional irrigation in SSC 1×10 minutes was completed at room 
temperature. Slides were washed in SSC 1×5 minutes at 60˚C and 
again for 1 minute at room temperature (in SSC). Vacuum centrifuge 
was used to dry microarray slides over 3 minutes, followed by laser 
scanning at 10 µm (Agilent Technologies, Santa Clara, CA, USA). Blue-
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Fuse software (BlueGnome, Ltd.) was used for analysis of microarray 
data on chromatin loss/gain across all 24 chromosomes. Aberrations 
were considered non-artifact if ≥15 probes deviated from normal 
limits as defined by the 24 sure platform. The published accuracy rate 
for this aCGH technique when applied to TE cells is 95% [34].
5.	Selection	criteria	for	cryopreservation
In both aCGH and control groups, blastocysts were graded [35] on 
a 1 to 6 scale determined by degree of expansion and hatching sta-
tus, as follows: grade 1 (early blastocyst): blastocoele <1/2 of total 
embryo volume; grade 2 (intermediate blastocyst): blastocoele ≥1/2 
of total embryo volume; grade 3 (full blastocyst): blastocoele fully oc-
cupies the embryo; grade 4 (expanded blastocyst): blastocoele is lar-
ger than early blastocyst and ZP demonstrates thinning; grade 5 (hat-
ching blastocyst): herniation of TE cells from the ZP; and grade 6 (hat-
ched blastocyst): blastocyst has escap ed the ZP. For blastocysts at 
grades 3 to 6, the inner cell mass (ICM) and TE were also graded. The 
ICM was graded as follows: A (many ICM cells packed together tight-
ly); B (several ICM cells grouped loosely) and C (very few ICM cells). TE 
was graded as follows: A (numerous TE cells forming multiple epithe-
lial layers); B (few TE cells consisting of a loose epithelium) and C (scarce 
large TE cells). For embryos in the aCGH group only one euploid blas-
tocyst was selected for transfer based on aCGH data and surplus eu-
ploid blastocysts were vitrified for later use [35]. In the non-aCGH (con-
trol) group, a single blastocyst was selected for fresh transfer based 
on morphological criteria only (i.e., no aCGH evaluation) and those 
blastocysts with good morphology (grade 3BB or above) were vitri-
fied the same day.
6.	Outcome	measures	and	statistical	analysis
The number of cryopreserved blastocysts was recorded and com-
pared for IVF patients where aCGH was utilized and for those where 
cryopreservation was determined by morphology alone. Differences 
between groups were assessed by chi-square test. A difference of 
p<0.05 was considered statistically significant. 
Results
A total of 188 IVF patients met inclusion criteria and 112 volunteered 
for enrollment (59.6%) during the four-month investigation. Of 56 
patients randomized to each group, some did not initiate IVF due to 
failure to complete required pre-IVF testing, they postponed treat-
ment until a later date, or for other reasons. For group A (morphology 
+ aCGH) and group B (morphology only) 55 and 48 IVF patients com-
pleted the study, respectively. There were no cancellations or compli-
cations for any patient in either study group.
For patients in group A, 425 of 457 blastocysts were biopsied and 
analyzed via aCGH (7.7 blastocysts/patient). Trophectoderm biopsy 
could not be completed in 7% of blastocysts (n=32) due to indistinct 
TE (poor morphology) or because they degenerated after biopsy. 
This evaluation revealed aneuploidy in 191/425 (44.9%) of blasto-
cysts. ‘No signal’ due to amplification failure occurred in 8 blastocysts. 
Among aneuploid blastocysts, 68/191 (35.6%) had single chromo-
some loss (monosomy) and 20.9% displayed single chromosome 
gain (trisomy). Approximately 43% of aneuploid blastocysts were 
chromosomally abnormal due to a severe, compound genetic defect 
where two or more chromosomes were affected. While chromosomal 
abnormalities were detected in all chromosomes, disruptions involv-
ing chromosomes 15, 16, 21, 22, and X were most frequently observ-
ed. Errors of chromosomes 4 and 6 were relatively uncommon. All 
patients in group A had at least one euploid blastocyst available for 
transfer on d6. For patients in group B, 389 blastocysts were micro-
scopically examined (8.1 blastocysts/patient). 
Among biopsied embryos in group A (n=425), euploidy was con-
firmed in 226 (53.1%). After fresh single embryo transfer, 64 (28.3%) 
surplus euploid embryos were cryopreserved for 51 study patients 
(92.7% of patients in this group). In group B, 389 good morphology 
blastocysts were identified and a single top quality blastocyst was 
selected for fresh transfer. As shown in Table 1, the cryopreservation 
yield for group B patients was 100% (48/48), because patients in this 
group all had at least one blastocyst remaining for cryopreservation. 
A total of 157 (40.4%) blastocysts were frozen in this group, a signifi-
cantly larger proportion than was cryopreserved in group A (p=0.017, 
by chi-squared analysis).
Discussion
Although the role of embryo cryopreservation will doubtless hold 
its essential niche in the modern IVF unit, it is not yet known exactly 
Table	1. Summary of IVF study patient data for blastocyst cryopreser-
vation following conventional morphology assessment plus compre-
hensive chromosomal screening via array CGH (group A), or conven-
tional morphology assessment only (group B)
Parameters A B
Patients enrolled   55   48
Patients with cryopreserved blastocysts   51   48
Blastocysts available for bx 457 n/a
Bx completed 425 n/a
Euploid blastocysts 226 n/a
Blastocysts remaining after ET 171 341
Cryopreserved blastocystsa   64 157
Demographic and clinical parameters were similar for both randomized groups. 
CGH, comparative genomic hybridization; Bx, biopsy; n/a, not applicable; ET, 
embryo transfer.
aA vs. B, p=0.017 (by chi-square test).
www.eCERM.org
Liu J et al.     Impact of aCGH on human embryo cryopreservation yield
55
how newer molecular testing techniques will affect this aspect of as-
sisted fertility treatment. As more practice jurisdictions move toward 
a mandatory single embryo transfer policy, it may be that pre-trans-
fer assessment of embryos by aCGH (or some other screening meth-
od) will become a regular procedure in IVF. Should fresh transfers be 
limited only to single embryos which undergo routine chromosomal 
screening, then the number of surplus cryopreserved embryos may 
be expected to rise. But thus far, clinical research has focused on ap-
plication of comprehensive chromosomal screening specifically for 
patients with known translocation, multiple implantation failure or 
recurrent pregnancy loss [7,19,29]. To our knowledge, a prospective 
study of cryopreservation yield following aCGH screening of embryos 
from IVF patients without such history (i.e., first cycle IVF, age <35 
and good prognosis) has not yet been conducted. The present inves-
tigation was undertaken to address this gap in the literature by pro-
viding measurements on rate of blastocyst cryopreservation as a func-
tion of aCGH inputs in this setting.
Among young patients with normal karyotype undertaking their 
first IVF cycle, with no miscarriage history or other predictors of poor 
prognosis, the present study found euploidy in only 226 of 425 blas-
tocysts (53.1%) as determined by aCGH testing. Although most (92.7%) 
patients in this group had at least one euploid blastocyst for cryo-
preservation after fresh transfers, just 67 blastocysts remained for 
cryopreservation in this group (29.6%). When embryo cryopreserva-
tion was performed on the basis of standard morphology assessment 
alone, all study 48 patients had at least one blastocyst available for 
cryopreservation. For this group, a total of 154 (39.6%) blastocysts 
were frozen. Since all study patients were <35 years of age, a very 
good chance to achieve surplus blastocysts for cryopreservation was 
expected regardless of randomization group (100% vs. 92.7%). How-
ever, a significantly lower (p=0.017) proportion of surplus blasto-
cysts were available for cryopreservation when aCGH testing was 
performed (39.6% vs. 29.6%). Interestingly, when cryopreservation 
yield is calculated on the basis of blastocysts remaining after fresh 
transfers rather than absolute (total) number of blastocysts, this dif-
ference between study groups persists. Such findings underscore the 
need for careful counseling for IVF patients throughout the treatment 
sequence, particularly as the critical time for embryo cryopreserva-
tion nears [36,37].
Our work extends prior observations to younger, lower-risk IVF po-
pulation and finds conventional morphological criteria alone to be 
insufficiently accurate to select blastocysts for cryopreservation. Fo-
cusing on a good-prognosis IVF patient population, the current study 
provides further evidence of substantial genetic abnormality (includ-
ing monosomy and complex aneuploidy [7,25,38]) in apparently 
normal blastocysts which otherwise would have been destined for 
cryostorage. We believe IVF patients should be counseled that the 
benefits of aCGH screening are likely to come at the cost of sharply 
limiting the number of surplus embryos available for cryopreserva-
tion. While we favor use of comprehensive chromosomal screening 
during IVF, these data place the shortcomings of standard embryo 
morphology -even for good prognosis IVF patients- in sharp relief. 
From this background an important clinical question emerges: If aCGH 
were to be become routinely integrated into the IVF treatment se-
quence, then what is the expected impact on the number of embry-
os available for cryopreservation?
Several limitations of our investigation should be acknowledged. 
Because blastocysts in our control group were selected by morphol-
ogy alone, they were cryopreserved without any genetic testing and 
therefore have an uncertain reproductive potential. This study was 
not designed to measure reproductive outcomes after thaw and trans-
fer. Additionally, we were not confident to include a power analysis 
prior to this investigation because the actual incidence of embryo 
aneuploidy in first-time IVF patients with no risk factors is unknown 
(i.e., if no significant difference had been identified, type II error could 
not have been excluded).
A changing public perception of better prognosis from IVF specifi-
cally when frozen embryos are thawed and transferred [39] has fur-
ther increased general awareness of cryopreservation’s central role in 
the advanced reproductive technologies [38,40,41]. Moreover, recent 
advancements in whole genome amplification and comprehensive 
chromosomal screening have permitted levels of human embryo 
surveillance that were not possible only a few years ago. These devel-
opments offer opportunities to verify an embryo’s genetic composi-
tion before cryopreservation. The present study suggests that desig-
nating an embryo for freezing without the benefit of information 
gained from aCGH would entail the preservation and storage of a re-
productively incompetent -albeit morphologically normal- embryo. 
A multi-center randomized clinical trial with a larger sample will be 
helpful to validate these preliminary findings.
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